Clinical trials
Muscle-Invasive Bladder Carcinoma clinical trials
Below are recruiting muscle-invasive bladder carcinoma clinical trials, each written for real people, not researchers. We’re tracking 59 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04900558Recruiting
Study outcomes after robotic bladder removal surgery
This trial follows adults who are planning to have a robotic radical cystectomy (surgery to remove the bladder and surrounding tissue) to learn what outcomes to expect. If you choose to join and meet the basics, it may help your team compare results and improve care for future patients.
Florence, TuscanyAges 18 years+ - NCT05072600RecruitingPhase 2
Pembrolizumab after complete bladder cancer treatment response
This trial studies pembrolizumab (an immunotherapy) in people with muscle-invasive bladder cancer who had a combined “trimodality” treatment and then achieved a complete response. The goal is to help control the cancer after the initial treatment is finished.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06170177Recruiting
Life after bladder removal surgery study
This study looks at how people feel and their health after having their bladder removed. It aims to understand quality of life after this surgery.
Milan, MIAges 18 years+ - NCT07855926Recruiting
Perioperative drug therapy for muscle-invasive bladder cancer
This study looks at different drug treatments given around the time of surgery for muscle-invasive bladder cancer. It aims to understand how well these treatments work and may help guide future care.
MunichAges 18 years+ - NCT06287541Recruiting
Do you need a second bladder surgery after a negative urine test?
This study looks at whether a second bladder surgery is still needed for people with high-risk bladder cancer who had a negative urine test after their first surgery.
Nanjing, JiangsuAges 18 years+ - NCT06441110RecruitingPhase 3
BCG instillation for medium- to high-risk bladder cancer
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
Fuzhou, FujianAges 18–75 - NCT07749924Recruiting
Watchful waiting vs. bladder chemotherapy for intermediate-risk bladder cancer
This study compares two approaches for people with intermediate-risk bladder cancer whose urine shows no signs of cancer after surgery. One group will be watched closely (active surveillance), while the other will receive chemotherapy directly into the bladder (intravesical chemotherapy). The goal is to see if surveillance alone can prevent unnecessary treatment while keeping the cancer controlled.
DaqingAges 18 years+ - NCT07756437Recruiting
Blood test for detecting bladder cancer DNA
This study is testing a simple blood test that looks for cancer DNA in your blood. The goal is to see if it can accurately detect muscle-invasive bladder cancer or upper tract urothelial cancer.
Ghent, East FlandersAges 18 years+ - NCT07747740RecruitingPhase 2
Bladder cancer treatment after BCG therapy fails
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
Moscow, MoscowAges 18 years+ - NCT07726602Recruiting
Tumor DNA blood test for muscle-invasive bladder cancer
This trial uses a blood test to look for small pieces of tumor DNA (ctDNA) after treatment for muscle-invasive bladder cancer. It aims to find out if the test can detect leftover or returning cancer earlier, helping guide next steps.
Portland, OregonAges 18 years+ - NCT07717242RecruitingPhase 2
Bladder cancer study testing a new drug combination before surgery
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
Guangzhou, GuangdongAges 18 years+ - NCT07647289RecruitingPhase 2
Immunotherapy plus chemotherapy before bladder cancer surgery
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07646145RecruitingPhase 2
Disitamab Vedotin Plus Mitomycin C for HER2-Positive Bladder Cancer
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
Taiyuan, ShanxiAges 18 years+ - NCT05790850Recruiting
Mindfulness and exercise plan before bladder surgery
This study tests whether a structured mindfulness and high-intensity exercise program before radical bladder surgery can help patients improve health and recovery. You may be asked to use monitoring devices and complete questionnaires during the study.
Charlottesville, VirginiaAges 18–90 - NCT06732531RecruitingPhase 1/Phase 2
Testing a new drug for high-risk bladder cancer that came back after BCG
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07483970RecruitingPhase 1
JL19001 alone or with BCG for high-risk non-muscle invasive bladder cancer
This trial tests a new drug called JL19001, given alone or with BCG (a standard bladder cancer treatment), for people with high-risk bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help prevent the cancer from coming back or getting worse.
Chengdu, SichuanAges 18 years+ - NCT04724928RecruitingPhase 2
PET-CT scan to guide bladder cancer treatment decisions
This Phase 2 study checks whether an FDG PET-CT scan can help doctors better predict bladder cancer risk and adjust treatment. You may still get standard bladder cancer care, but the study uses the scan results to help decide how aggressive treatment should be.
GhentAges 18 years+ - NCT07475806RecruitingPhase 2
Bladder-sparing drug combo for muscle-invasive bladder cancer
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
Little Rock, ArkansasAges 18 years+ - NCT07475403RecruitingPhase 2
Immunotherapy guided by urine DNA for high risk bladder cancer
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
TianjinAges 18 years+ - NCT07339761Recruiting
Sexual health support for bladder cancer patients
This study from the University of Aarhus looks at ways to support sexual health in people who have been treated for bladder cancer. If you are a Danish-speaking adult who had bladder cancer treatment about a year ago and have noticed changes in sexual function, you may be able to join.
AarhusAges 18 years+ - NCT07302230Recruiting
Home exercise app for bladder cancer patients
This trial tests whether a home-based physical activity program using a smartphone app helps people with non-muscle invasive bladder cancer become more active compared to a health education group. It's designed for those who are not very active and want to improve their health.
Seattle, WashingtonAges 18 years+ - NCT06493552RecruitingPhase 2/Phase 3
Testing sEphB4-HSA in EphrinB2-high bladder cancer
This trial tests a new drug called sEphB4-HSA for people with a specific type of bladder cancer (urothelial carcinoma) that has high levels of a protein called EphrinB2. The study aims to see if this drug can shrink tumors or prevent them from growing, and it compares it to standard treatments like chemotherapy or immunotherapy.
Santa Monica, CaliforniaAges 18 years+ - NCT07234968Recruiting
Stent vs no stent after bladder removal surgery
This study looks at whether leaving a small tube (ureteral stent) in place after bladder removal helps recovery. It compares people who get a stent to those who don't, focusing on problems like leaks or infections after surgery.
Philadelphia, PennsylvaniaAges 18–85 - NCT06257017RecruitingPhase 2
Using DNA tests to guide chemotherapy after bladder cancer surgery
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
Hong Kong, Hong KongAges 18–70
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Muscle-Invasive Bladder Carcinoma trials by city
Studies with a site in or near these metro areas.
Muscle-Invasive Bladder Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for muscle-invasive bladder carcinoma?
- Yes. Clin2 currently lists 59 recruiting muscle-invasive bladder carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a muscle-invasive bladder carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a muscle-invasive bladder carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Recurrent Non-Muscle Invasive Bladder Carcinoma
- Non Muscle Invasive Bladder Cancer
- Muscle Invasive Bladder Cancer (MIBC)
- Non-Muscle Invasive Bladder Neoplasms
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.